Balyasny Asset Management LLC Fulcrum Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
A detailed history of Balyasny Asset Management LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 15,709 shares of FULC stock, worth $135,097. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,709
Previous 105,179
85.06%
Holding current value
$135,097
Previous $709,000
79.13%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding FULC
# of Institutions
136Shares Held
44.2MCall Options Held
3.12MPut Options Held
128K-
Rtw Investments, LP New York, NY5.85MShares$50.3 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$31.9 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$24.5 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$21.8 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$20.2 Million10.72% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $448M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...